Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fluorouracil-refractory metastatic colon cancer

Journal of Clinical Oncology

Volumn 21, Issue 6, 2003, Pages 1125-1132

  Chester, John D ^a   Joel, Simon P ^a   Cheeseman, Susan L ^a   Hall, Geoffrey D ^a   Braun, Michael S ^a   Perry, Jackie ^a   Davis, Theresa ^a   Button, Christopher J ^a   Seymour, Matthew T ^a  

^a Northern and Yorkshire Clinical Trials and Research Unit

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; CYCLOSPORIN; FLUOROURACIL; IRINOTECAN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DRUG DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG SAFETY; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; ADULT; AGED; BLOOD; CANCER STAGING; COLON TUMOR; DRUG RESISTANCE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; CYCLOSPORINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 0037445190     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.08.049     Document Type: Article

References (35)

1. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412, 1998
2. Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1998
3. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355: 1041-1047, 2000
4. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000
5. Rothenberg ML, Meropol NJ, Poplin EA, et al: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 19:3801-3807, 2001
6. Relling MV, Dervieux T: Pharmacogenetics and cancer therapy. Nature Rev Cancer 1:99-108, 2001
7. Innocenti F, Ratain MJ: Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer 38:639-644, 2002
8. Mathijssen RH, Verweij J, de Jonge MJ, et al: Impact of body-size measures on irinotecan clearance: Alternative dosing recommendations. J Clin Oncol 20:81-87, 2002
9. Mathijssen RH, van Alphen RJ, Verweij J, et al: Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182-2194, 2001
10. Ratain MJ: Insights into the pharmacokinetics and pharmacodynamics of irinotecan. Clin Cancer Res 6:3393-3394, 2000
11. Chu XY, Kato Y, Ueda K, et al: Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters. Cancer Res 58:5137-5143, 1998
12. Sugiyama Y, Kato Y, Chu X: Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: Role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother Pharmacol 42:S44-S49, 1998 (suppl)
13. Kehrer DF, Yamamoto W, Verweij J, et al: Factors involved in prolongation of the terminal disposition phase of SN-38: Clinical and experimental studies. Clin Cancer Res 6:3451-3458, 2000
14. Gupta E, Lestingi TM, Mick R, et al: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725, 1994
15. Ratain MJ: Irinotecan dosing: Does the CPT in CPT-11 stand for "can't predict toxicity"? J Clin Oncol 20:7-8, 2002
16. Ratain MJ, Goh BC, Iyer L, et al: A phase I study of irinotecan (CPT-11) with pharrnacokinetic modulation by cyclosporine A (CSA) and phenobarbital (PB). Proc Am Soc Clin Oncol 18:202a, 1999 (abstr 777).
17. Gupta E, Safa AR, Wang X, et al: Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res 56:1309-1314, 1996
18. Foxwell BM, Mackie A, Ling V, et al: Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol 36:543-546, 1989
19. Kivisto KT, Kroemer HK, Eichelbaum M: The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions. Br J Clin Pharmacol 40:523-530, 1995
20. Fahr A: Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 24:472-495, 1993
21. Aspeslet LJ, LeGatt DF, Murphy G, et al: Effect of assay methodology on pharmacokinetic differences between cyclosporine Neoral and Sandimmune formulations. Clin Chem 43:104-108, 1997
22. Malingre MM, Terwogt JM, Beijnen JH, et al: Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol 18:2468-2475, 2000
23. 2 given every-other-week in previously treated colorectal cancer patients. Proc Am Soc Clin Oncol 17:284a, 1998 (abstr 1092).
24. Fagbemi S, Iyer L, Mani S, et al: Phase I and pharmacokinetic study of irinotecan (CPT-11) administered with cyclosporine (CSA). Proc Am Soc Clin Oncol 16:219a, 1997 (abstr 766.5).
25. Pabst G, Jaeger H: Review of methods and criteria for the evaluation of bioequivalence studies. Eur J Clin Pharmacol 38:5-10, 1990
26. Ratain MJ, Gupta E (inventors). Camptothecin drug combinations and methods with reduced side-effects. United States Patent No. 5,786,344, July 28, 1998.
27. de Jonge MJ, Sparreboom A, Planting AS, et al: Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors. J Clin Oncol 18:187-194, 2000
28. Abigerges D, Chabot GG, Armand JP, et al: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221, 1995
29. Canal P, Gay C, Dezeuze A, et al: Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 14:2688-2695, 1996
30. Iyer L, Ramirez J, Shepard DR, et al: Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother Pharmacol 49:336-341, 2002
31. Lush RM, Meadows B, Fojo AT, et al: Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. J Clin Pharmacol 37:123-128, 1997
32. Chen ZS, Kawabe T, Ono M, et al: Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol 56:1219-1228, 1999
33. Kehrer DF, Mathijssen RH, Verweij J, et al: Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 20:3122-3129, 2002
34. Jordan K, Grothey A, Kellner O, et al: Randomized phase II trial of capecitabine plus irinotecan versus capecitabine plus oxaliplatin as first-line therapy in advanced colorectal cancer: Results of an interim analysis. Proc Am Soc Clin Oncol 21:103b, 2002 (abstr 2225).
35. Yamamoto W, Verweij J, de Bruijn P, et al: Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells. Anticancer Drugs 12:419-432, 2001